Anti-Huntingtin antibody - N-terminal (ab83916)

Overview

  • Product nameAnti-Huntingtin antibody - N-terminalSee all Huntingtin primary antibodies ...
  • Description
    Rabbit polyclonal to Huntingtin - N-terminal
  • Tested applicationsICC/IF, WB, ELISAmore details
  • Species reactivity
    Reacts with: Mouse, Rat, Human
  • Immunogen

    A synthetic peptide corresponding to a N terminal region of human Huntingtin

  • Positive control
    • Mouse brain extract. SKNSH cell line (IF/ICC)

Properties

  • FormLiquid
  • Storage instructionsShipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid repeated freeze / thaw cycles.
  • Storage bufferpH: 7.40
    Constituents: 50% Glycerol, 0.42% Potassium phosphate, 0.88% Sodium chloride
  • Concentration information loading...
  • PurityImmunogen affinity purified
  • Clonality Polyclonal
  • IsotypeIgG
  • Research Areas

Applications

Our Abpromise guarantee covers the use of ab83916 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
ICC/IF Use a concentration of 5 µg/ml.
WB Use a concentration of 0.1 µg/ml. Detects a band of approximately 330 kDa (predicted molecular weight: 348 kDa).
ELISA Use at an assay dependent dilution.

Target

  • FunctionMay play a role in microtubule-mediated transport or vesicle function.
  • Tissue specificityExpressed in the brain cortex (at protein level). Widely expressed with the highest level of expression in the brain (nerve fibers, varicosities, and nerve endings). In the brain, the regions where it can be mainly found are the cerebellar cortex, the neocortex, the striatum, and the hippocampal formation.
  • Involvement in diseaseDefects in HTT are the cause of Huntington disease (HD) [MIM:143100]. HD is an autosomal dominant neurodegenerative disorder characterized by involuntary movements (chorea), general motor impairment, psychiatric disorders and dementia. Onset of the disease occurs usually in the third or fourth decade of life and symptoms progressively worsen leading to death in 10 to 20 years. Onset and clinical course depend on the degree of poly-Gln repeat expansion, longer expansions resulting in earlier onset and more severe clinical manifestations. HD affects 1 in 10,000 individuals of European origin. Neuropathology of Huntington disease displays a distinctive pattern with loss of neurons, especially in the caudate and putamen (striatum).
  • Sequence similaritiesBelongs to the huntingtin family.
    Contains 10 HEAT repeats.
  • DomainThe N-terminal Gln-rich and Pro-rich domain has great conformational flexibility and is likely to exist in a fluctuating equilibrium of alpha-helical, random coil, and extended conformations.
  • Post-translational
    modifications
    Cleaved by apopain downstream of the polyglutamine stretch. The resulting N-terminal fragment is cytotoxic and provokes apoptosis.
    Forms with expanded polyglutamine expansion are specifically ubiquitinated by SYVN1, which promotes their proteasomal degradation.
  • Cellular localizationCytoplasm. Nucleus. The mutant Huntingtin protein colocalizes with AKAP8L in the nuclear matrix of Huntington's disease neurons.
  • Information by UniProt
  • Database links
  • Alternative names
    • AI256365 antibody
    • C430023I11Rik antibody
    • HD antibody
    • HD protein antibody
    • HD_HUMAN antibody
    • HDH antibody
    • HTT antibody
    • Huntingtin antibody
    • HUNTINGTON CHOREA antibody
    • Huntington disease protein antibody
    • Huntington's disease protein homolog antibody
    • IT 15 antibody
    • IT15 antibody
    • OTTMUSP00000026909 antibody
    • ZHD antibody
    see all

Anti-Huntingtin antibody - N-terminal images

  • All lanes : Anti-Huntingtin antibody - N-terminal (ab83916) at 0.1 µg/ml

    Lane 1 : Mouse brain extract
    Lane 2 : Mouse brain extract with blocking peptide at 1 µg/ml


    Predicted band size : 348 kDa
    Observed band size : 330 kDa (why is the actual band size different from the predicted?)
    Additional bands at : <250 kDa. We are unsure as to the identity of these extra bands.
  • ICC/IF image of ab83916 stained SKNSH cells. The cells were 4% formaldehyde fixed (10 min) and then incubated in 1%BSA / 10% normal goat serum / 0.3M glycine in 0.1% PBS-Tween for 1h to permeabilise the cells and block non-specific protein-protein interactions. The cells were then incubated with the antibody (ab83916, 5µg/ml) overnight at +4°C. The secondary antibody (green) was ab96899, DyLight® 488 goat anti-rabbit IgG (H+L) used at a 1/250 dilution for 1h. Alexa Fluor® 594 WGA was used to label plasma membranes (red) at a 1/200 dilution for 1h. DAPI was used to stain the cell nuclei (blue) at a concentration of 1.43µM.

References for Anti-Huntingtin antibody - N-terminal (ab83916)

ab83916 has not yet been referenced specifically in any publications.

Product Wall

Application Immunoprecipitation
Immuno-precipitation step Protein G
Sample Saccharomyces cerevisiae Cell lysate - whole cell (Yeast cells expressing HttEx1)
Specification Yeast cells expressing HttEx1
Treatment Expression is induced by 2% Galactose
Total protein in input 5e+007 cells
Username

Abcam user community

Verified customer

Submitted Mar 26 2014

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"